Trump’s ‘rad­i­cal’, ‘hor­ri­ble’ ex­ec­u­tive or­ders on drug pric­ing earn a C-suite back­lash this week — with one threat to do more over­seas

Once the pan­dem­ic erupt­ed in the US, Big Phar­ma en­joyed a brief pe­ri­od of de­tente — if not ac­tu­al­ly warm re­la­tions — with the Trump ad­min­is­tra­tion.

Af­ter years of crit­i­ciz­ing high drug prices and threat­en­ing leg­is­la­tion that would curb the in­dus­try’s pric­ing free­dom, the pres­i­dent warm­ly en­cour­aged the in­dus­try’s com­mit­ment to a pell mell race to new vac­cines and drugs to fight Covid-19 — of­ten at speeds that would have been con­sid­ered im­pos­si­ble back in Jan­u­ary. And it raised the pos­si­bil­i­ty that bio­phar­ma could fi­nal­ly find a way to achieve some kind of pop­u­lar­i­ty af­ter years of pub­lic tox­i­c­i­ty.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE